Tizona Therapeutics is harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Cancers use various strategies to evade detection by the immune system. Tizona is creating therapeutics that can suppress these strategies to mediate tumor detection and clearance. Their lead program, TTX-080, is a first-in-class antibody against the protein HLA-G. HLA-G is normally expressed at the maternal-fetal interface and certain sites of immune privilege. In cancer, HLA-G mediates potent immune suppression. By targeting HLA-G with their antibody, Tizona is advancing their therapy into clinical studies for patients with advanced cancers.

Tizona Therapeutics

Drug notes:

About:

Jobs: